Kaoru Tamura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6196804/publications.pdf

Version: 2024-02-01

932766 752256 34 652 10 20 citations h-index g-index papers 35 35 35 1144 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications, 2016, 4, 79.	2.4	189
2	Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. Journal of Neurosurgery, 2010, 113, 310-318.	0.9	113
3	Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas. Acta Neuropathologica, 2017, 133, 445-462.	3.9	64
4	Malignant transformation eight years after removal of a benign epidermoid cyst: a caseâ£report. Journal of Neuro-Oncology, 2006, 79, 67-72.	1.4	61
5	TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathologica, 2021, 142, 323-338.	3.9	58
6	Fine-Tuning Approach for Segmentation of Gliomas in Brain Magnetic Resonance Images with a Machine Learning Method to Normalize Image Differences among Facilities. Cancers, 2021, 13, 1415.	1.7	28
7	TERT promoter mutation confers favorable prognosis regardless of $1p/19q$ status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathologica Communications, 2020, 8, 201.	2.4	27
8	A Questionnaire to Assess the Challenges Faced by Women Who Quit Working as Full-Time Neurosurgeons. World Neurosurgery, 2020, 133, 331-342.	0.7	22
9	Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. Acta Neuropathologica, 2017, 133, 321-324.	3.9	18
10	12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors. Neuro-Oncology, 2022, 24, 834-846.	0.6	16
11	LAPTM4B-35 is a novel prognostic factor for glioblastoma. Journal of Neuro-Oncology, 2017, 132, 295-303.	1.4	14
12	Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts. Neuro-Oncology, 2022, 24, 1246-1258.	0.6	14
13	Low tumor cell content predicts favorable prognosis in germinoma patients. Neuro-Oncology Advances, 2021, 3, vdab110.	0.4	8
14	ATRX status correlates with $11 {\rm \^AC}$ -methionine uptake in WHO grade II and III gliomas with IDH1 mutations. Brain Tumor Pathology, 2017, 34, 20-27.	1.1	7
15	Correlation of Intraoperative 5-ALA-Induced Fluorescence Intensity and Preoperative 11C-Methionine PET Uptake in Glioma Surgery. Cancers, 2022, 14, 1449.	1.7	5
16	Occipital Condyle Osteoid Osteoma with Severe Occipital Pain that Disappeared after Surgical Resection. NMC Case Report Journal, 2015, 2, 128-131.	0.2	3
17	Ischemic Stroke with Multiple Cerebral Artery Stenosis in a Patient with an Anaplastic Astrocytoma during Bevacizumab Treatment: A Case Report. NMC Case Report Journal, 2022, 9, 13-17.	0.2	2
18	Usefulness of ¹¹ C-Methionine Positron Emission Tomography for Monitoring of Treatment Response and Recurrence in a Glioblastoma Patient on Bevacizumab Therapy: A Case Report. Case Reports in Oncology, 2018, 11, 442-449.	0.3	1

#	Article	IF	CITATIONS
19	MPC-1 DNA methylome analysis suggested the presence of "true―lDH-wildtype lower-grade gliomas. Neuro-Oncology Advances, 2021, 3, vi15-vi16.	0.4	1
20	PATH-37. PROGNOSTIC ROLE OF TERT PROMOTER MUTATIONS IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA. Neuro-Oncology, 2019, 21, vi151-vi151.	0.6	0
21	MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS. Neuro-Oncology Advances, 2019, 1, ii23-ii23.	0.4	0
22	NI-06 MOLECULAR DIAGNOSIS, 11C-METHIONINE UPTAKE AND PROGNOSIS IN GRADE 2 AND 3 GLIOMAS. Neuro-Oncology Advances, 2019, 1, ii26-ii26.	0.4	0
23	Stratified monotherapy approach according to MGMT methylation status in elderly patients with glioblastoma Journal of Clinical Oncology, 2019, 37, 2050-2050.	0.8	0
24	GCT-43. GAIN OF SHORT ARM OF CHROMOSOME 12 IS A MOLECULAR MARKER TO PREDICT PROGNOSIS AND REPRESENTS AN EARLY EVENT IN TUMORIGENESIS IN INTRACRANIAL GERM CELL TUMORS. Neuro-Oncology, 2020, 22, iii336-iii336.	0.6	0
25	RONC-18. ANALYSIS OF BRAIN TUMOR INDUCED BY IRRADIATION IN CHILDHOOD - A SINGLE INSTITUTIONAL ANALYSIS. Neuro-Oncology, 2020, 22, iii458-iii459.	0.6	0
26	GCT-52. TRANSCRIPTOME OF CENTRAL NERVOUS SYSTEM GERM CELL TUMOR REVEALS ITS PATHOGENESIS AND CONTRASTS WITH TESTICULAR COUNTERPARTS IN INTEGRATED OMICS ANALYSIS. Neuro-Oncology, 2020, 22, iii338-iii339.	0.6	0
27	HGG-50. TWO CASES OF H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA OF CERVICAL SPINAL CORD. Neuro-Oncology, 2020, 22, iii352-iii353.	0.6	0
28	Occipital Condyle Osteoid Osteoma with Severe Occipital Pain that Disappeared after Surgical Resection. NMC Case Report Journal, 2015, 2, 128-131.	0.2	0
29	NIMG-29. DEVELOPING AUTOMATIC SEGMENTATION METHOD FOR BRAIN TUMOR MR IMAGES THAT CAN BE USED AT MULTIPLE FACILITIES. Neuro-Oncology, 2020, 22, ii153-ii154.	0.6	0
30	PEDT-1 Integrated diagnoses of pediatric gliomas in our institute by cIMPACT-NOW recommendations. Neuro-Oncology Advances, 2021, 3, vi10-vi11.	0.4	0
31	Branch-like enhancement on contrast enhanced MRI is a specific finding of cerebellar lymphoma compared with other pathologies. Scientific Reports, 2022, 12, 3591.	1.6	0
32	NI-10 Reclassification of diffuse gliomas based on molecular diagnosis -evaluation of methionine uptake and treatment outcome Neuro-Oncology Advances, 2021, 3, vi19-vi19.	0.4	0
33	BOT-3 Prognostic Factors of CNS Germ Cell Tumors; Molecular and Histopathological Analyses on 154 Cases from the iGCT Consortium. Neuro-Oncology Advances, 2021, 3, vi8-vi9.	0.4	0
34	NI-8 Molecular diagnostic prediction combining T2-FLAIR mismatch sign, calcification, and methionine PET in grade II and III gliomas. Neuro-Oncology Advances, 2021, 3, vi19-vi19.	0.4	0